eRapa

DRUG2 trials

Sponsors

Biodexa Limited, Rapamycin Holdings Inc., Robert Svatek

Conditions

Familial adenomatous polyposis (FAP)Non-muscle Invasive Bladder Cancer

Phase 2

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Active, not recruitingNCT04375813

Robert SvatekNon-muscle Invasive Bladder Cancer

Start: 2021-01-25End: 2027-07-01Target: 166Updated: 2026-06-03

Phase 3

A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients with Familial Adenomatous Polyposis

RecruitingCTIS2025-522946-37-00

Biodexa Limited, Rapamycin Holdings Inc.Familial adenomatous polyposis (FAP)

Start: 2025-11-24Target: 22Updated: 2026-01-27

Related Papers

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Journal for ImmunoTherapy of Cancer2021-03-0128 citations